Apr 25, 2023 / 04:30PM GMT
Brad Canino - Stifel Financial Corp. - Analyst
Okay, great. Thanks, everyone, for continuing to join us for our public-company fireside chat session at our inaugural Targeted Oncology Days here at Stifel. My name is Brad Canino, senior analyst here. My other colleagues, Ben Burnett and Steve Willey are also hosting fireside throughout the day.
So thank you again for joining us, and I'm happy to host the next one with Cogent Biosciences. We have CEO, Andy Robbins, here to have the fireside chat with me. If you'd like, Andy, give some quick introductory comments for the company and your lead compound, and then we'll go from there.
Andy Robbins - Cogent Biosciences, Inc. - CEO & President
Sure, thanks. Thanks, Brad, and thanks for inviting us to the conference; happy to be here. Just very quickly for folks listening in, almost certainly, I'll be making forward-looking statements today, for a better fuller characterization of the risks. We just point you to our recent SEC filings for that full discussion.
So I'm, as Brad said, Andy Robbins,
Cogent Biosciences Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 25, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers